Get the latest updates on new actionable drivers in NSCLC with these expert perspectives from our satellite symposium in Chicago. A variety of topics were covered, including advances in molecular testing, such as next-generation sequencing and liquid biopsy, new data on emerging agents, and how these new data should be applied in clinical practice.
0.75 AMA PRA Category 1 Credit(s)™
Jul 1, 2019
Jul 1, 2020
Ross Camidge, MD, PhDUniversity of Colorado Cancer Center
Aurora, Colorado, United States
Frank Griesinger, MD, PhDPius-Hospital Oldenburg
Keith Kerr, MBChB, FRCPathAberdeen University Medical School
Aberdeen Royal Infirmary
Paul K. Paik, MDMemorial Sloan Kettering Cancer Center
New York, New York, United States
James C-H Yang, MD, PhDNational Taiwan University Hospital
National Taiwan University Cancer Center
Setting the stage: How precision medicine transformed the treatment algorithm of advanced NSCLC thus far
Ross Camidge, MD, PhD
Identifying new actionable targets: Use of broad molecular profiling in daily practice
Keith Kerr, MBChB, FRCPath
MET-altered NSCLC: Current and emerging treatment strategies
Paul K. Paik, MD
Updates on targeting HER2, RET, and NTRK in advanced NSCLC
Frank Griesinger, MD, PhD
Managing acquired resistance to EGFR-TKI: Focus on targeting bypass resistance mechanisms
James C-H Yang, MD, PhD
This educational activity is designed for oncologists (community and academic), pulmonologists, pathologists, oncology fellows, and other healthcare professionals involved in the management of patients with lung cancer.
After successful completion of this educational activity, participants should be able to:
- Assess the role of broad molecular profiling and the use of liquid biopsy in advanced NSCLC
- Select and evaluate treatment options for patients identified with oncogene drivers such as MET exon 14–skipping mutations or MET amplification, RET, HER2, and NTRK
- Analyze efficacy and safety data of emerging agents in patients harboring new driver mutations and discuss clinical applications of new data
- Explain strategies to overcome acquired resistance to targeted therapy such as EGFR-TKI, including emerging combination targeted-treatment approaches
This educational activity is supported by a grant from EMD Serono, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 0.75 hour(s)
To contact Postgraduate Institute for Medicine, please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Camidge has disclosed ad hoc advisory boards/consultations for AstraZeneca, Arrys/Kyn, Bio-Thera Data Safety Monitoring Board, Blueprint, Bristol-Myers Squibb, CBT Pharmaceuticals, Daichii-Sankyo ILD Adjudication Committee, G1 Therapeutics Data Safety Monitoring Board, Hansoh Pharmaceuticals Scientific Review Committee, Hengrui, Inivata, Regeneron, Ribon, Roche/Genentech, and Takeda. He also disclosed his prinicipal investigator role on company sponsored trials at this institution from AbbVie, AstraZeneca, Bristol-Myers Squibb, Hansoh, Lycera, MedIMmune, Merck, Pfizer, Phosplatin, Roche/Genentech, Seattle Genetics, Symphogen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Griesinger has disclosed consulting fees for non-CME/CE services received directly from a commercial interest and contracted research for AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Merck Sharpe and Dohme, Novartis, Pfizer, Roche, Siemens, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Kerr has disclosed consulting fees from AstraZeneca, Archer Dx, Bayer, Merck Sharpe and Dohme, Merck Serono, Pfizer, Roche, and Ventana. He also received fees for non-CME/CE services directly from AstraZeneca, Boehringer Ingelheim, Merck Sharpe and Dohme, Merck Serono, Pfizer, Roche, and Ventana. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Paik has disclosed consulting fees from AbbVie, Boehringer Ingelheim, Celgene, and Lily. He also did contracted research for Celgene and EMD Serono. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Yang has disclosed consulting fees from AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Hansoh Pharmaceuticals, Merck Serono, Merck Sharpe and Dohme, Novartis, Ono Pharmaceuticals, Pfizer, Roche/Genentech, and Takeda Pharmaceuticals. He also received fees for non-CME/CE services directly from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai Pharmaceutical, Eli Lilly, Merck Sharpe and Dohme, Novartis, Ono Pharmaceuticals, Pfizer, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Tristin Abair, PhD (medical writer) – worked on non-CME certified projects in the last 12 months supported by AbbVie Inc.; Astellas Pharma Inc.; Bayer AG; Novartis International AG; and Jazz Pharmaceuticals
- Susan McKinney (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.